排序方式:
1.BNT162b2 effectiveness after extending the primary-series dosing interval in children and adolescents
Lai, FTT, Fan, M, Hu
More...
Lai, FTT, Fan, M, Huang, C, Wong, ICK
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 563-564
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
2.Cardiovascular risks in prostate cancer patients undergoing androgen deprivation therapy among the southern Chinese: A population-based cohort study
Li, TH, Yan, VKC, Ka
More...
Li, TH, Yan, VKC, Kang, W, Ye, XX, El Helali, A, Lee, SF, Shami, J, Li, X, Yiu, HHE, Wong, ICK, Chan, EWY
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 107-107
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
3.Association between mortality and warfarin comparing with direct oral anticoagulants: A population-based cohort study
Wang, Z, Matthewman,
More...
Wang, Z, Matthewman, J, Tazare, JR, Cheung, KS, Chui, CSL, Wong, ICK, Douglas, I, Wong, AYS
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 371-372
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
4.Rates of antidepressant, antiepileptic and anxiolytic prescribing among people living with dementia during the COVID-19 pandemic: A multinational interrupted time-series analysis
Bryant, OK, Luo, H,
More...
Bryant, OK, Luo, H, Man, KKC, Chai, Y, Torre, CO, Lin, XY, Seager, S, Fortin, S, Lee, DY, Wei, L, Lau, W, Wong, ICK
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 209-210
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
5.Effectiveness of molnupiravir and nirmatrelvir-ritonavir in patients hospitalized with COVID-19: A target trial emulation study
Yan, VKC, Wan, EYF,
More...
Yan, VKC, Wan, EYF, Mok, AHY, Chan, EWY, Wong, ICK
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 264-264
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
6.Carditis risk following COVID-19 vaccination with mRNA (BNT162b2) or inactivated (CoronaVac): A self-controlled cases series and a case-control study
Chui, CSL, Lai, FTT,
More...
Chui, CSL, Lai, FTT, Fan, M, Wong, ICK
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 149-149
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
7.Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection: A population-based cohort study
Xiong, X, Lui, DTW,
More...
Xiong, X, Lui, DTW, Chung, MSH, Au, ICH, Lai, FTT, Wan, EYF, Chui, CSL, Li, X, Cheng, FWT, Cheung, CL, Chan, EWY, Lee, CH, Woo, YC, Tan, KCB, Wong, CKHK, Wong, ICK
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 109-109
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
8.Impact of introducing infliximab biosimilars on total infliximab consumption and originator infliximab prices in eight regions: An interrupted time-series analysis
Peng, K, Blais, JE,
More...
Peng, K, Blais, JE, Pratt, NL, Guo, JJ, Hillen, JB, Stanford, T, Ward, M, Lai, ECC, Shin, JY, Tong, XN, Fan, M, Wing, F, Cheng, T, Wu, J, Yeung, WWY, Lau, CS, Leung, WK, Wong, ICK, Li, X
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 167-167
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
9.Treatment-resistant depression and risk of autoimmune diseases: Evidence from a nested case-control study
Chan, VKY, Luo, H, C
More...
Chan, VKY, Luo, H, Chan, SSM, Yeung, WWY, Peng, K, Tong, XN, Lam, MPS, Wong, ICK, Li, X
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 237-237
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
10.The use of ADHD medication and the risk of suicide attempt: A multinational population-based self-controlled case series study
Chan, AYL, Chan, A,
More...
Chan, AYL, Chan, A, Lai, ECC, Park, S, Shen, CY, Shin, JY, Wei, L, Man, KKC, Wong, ICK
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 19-20
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
11.Sex-specific comparative effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation-A systematic review and meta-analysis
Chobanov, J, Mongkho
More...
Chobanov, J, Mongkhon, P, Wang, ZX, Man, KKC, Wong, ICK, Lau, W
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 400-401
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
12.Risk of hip fracture in the elderly following Covid-19 vaccination in Hong Kong: A self-controlled case series study
Zhang, XW, Cheung, C
More...
Zhang, XW, Cheung, CL, Wong, ICK, Sing, CW
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 638-639
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
13.A retrospective cohort study to evaluate the impact of chemotherapy dose delays on survival in breast cancer patients in England
Steventon, L, Chambe
More...
Steventon, L, Chambers, P, Man, KKC, Kipps, E, Forster, M, Wong, ICK, Shah, S, Miller, R
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2023,
Volume 32,
Pages 256-257
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.4
14.Survival analysis of riluzole for patients with motor neuron disease in Hong Kong: A population-based cohort study
Fan, M, Lau, GK, Li,
More...
Fan, M, Lau, GK, Li, X, Cheung, EC, Gao, L, Wong, I, Chui, CS
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 335-335
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6
15.Use of riluzole and risk of hospitalization for patients with motor neuron disease in Hong Kong: A self-controlled case series study
Fan, M, Lau, GK, Li,
More...
Fan, M, Lau, GK, Li, X, Gao, L, Cheung, EC, Wong, I, Chui, CS
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 335-336
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6
16.Time series analysis of blood pressure-lowering drug prescribing trends among dementia patients in Hong Kong
Cheung, EC, Chui, CS
More...
Cheung, EC, Chui, CS, Leung, M, Lau, GK, Luo, H, Wan, EY, Wong, I
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 298-299
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6
17.Association between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: A systematic review and meta-analysis
Wang, ZX, Wong, K, W
More...
Wang, ZX, Wong, K, Wong, I, Man, K
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 470-470
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6
18.Association of maternal levothyroxine use during pregnancy with offspring birth and neurodevelopmental outcomes
Ge, MQ, Cheung, EC,
More...
Ge, MQ, Cheung, EC, Man, K, Ip, P, Leung, WC, Li, G, Kung, A, Cheung, CL, Wong, I
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 474-475
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6
19.The impact of polypharmacy on restarting antidepressant treatment in individuals with comorbid depression and type 2 diabetes: A UK primary care cohort study
Jeffery, A, Walters,
More...
Jeffery, A, Walters, K, Osborn, D, Wong, I, Hayes, JFF
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 544-544
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6
20.Attention deficit hyperactivity disorder medication consumption in 64 countries from 2015 to 2019: A longitudinal study
Chan, A, Ma, TT, Lau
More...
Chan, A, Ma, TT, Lau, W, Ip, P, Coghill, D, Le Gao,, Jani, Y, Hsia, Y, Wei, L, Taxis, K, Simonoff, E, Taylor, D, Lum, TY, Man, K, Wong, I
Less
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY[1053-8569],
Published 2022,
Volume 31,
Pages 70-71
收錄情况:
WOS
WOS核心合集引用: 0
2023影響因子:
2.4
发表年影響因子:
2.6